University of Yucatan launches stem cell laboratory – The Yucatan Times
The Yucatan Times |
University of Yucatan launches stem cell laboratory
The Yucatan Times MERIDA — The Faculty of Dentistry of the Autonomous University of Yucatan (UADY, for its acronym in Spanish) has inaugurated its Translational Cell Laboratory, the only one of its kind in the southeast of the country, where research will be carried … |
KUNC |
FDA Approves First Gene Therapy For Leukemia
KUNC The Food and Drug Administration on Wednesday announced what the agency calls a “historic action” — the first approval of a cell-based gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it … FDA approval brings first gene therapy to the United StatesFDA.gov Ben Taub Hospital – Harris Health SystemHarris Health System ‘This Is Surreal’: Houston Dialysis Center Struggles To Treat PatientsNPR NPR –National Cancer Institute all 34 news articles » |
OncLive |
Novartis Sets a Price of $475000 for CAR T-Cell Therapy
OncLive Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and … First CAR T-Cell ‘Living Drug’ Approved by FDAMedscape FDA Approves First Gene Therapy For LeukemiaNPR FDA approves a ‘historic’ new type of leukemia treatmentToday.com MedPage Today –Scientific American –FDA.gov all 232 news articles » |
Express.co.uk |
Cancer breakthrough: Scientists hail gene therapy treatment which KILLS cancer cells
Express.co.uk CAR-T cell treatment is the first gene therapy to be made available and one of a wave of expensive custom-made “living drugs” being tested against blood cancers. The US Food and Drug Administration agency has hailed its approval as historic. |
Wall Street Journal (subscription) |
FDA Approves Pioneering Cancer Treatment With $475000 Price Tag
Wall Street Journal (subscription) The Food and Drug Administration approved a first-of-its kind cancer therapy aimed at bolstering a patient’s own immune cells, while the drugmaker behind the treatment attempted to allay worry over the high cost of the procedure. Swiss pharmaceuticals … |
Fred Hutch News Service |
Fred Hutch statement regarding FDA action on CTL019 immunotherapy
Fred Hutch News Service SEATTLE — AUG. 30, 2017 — Today the U.S. Food and Drug Administration approved the use of a new Novartis immunotherapy drug, CTL019, as a treatment for advanced leukemia in children and young adults. This latest FDA ruling validates the … New ‘hit-and-run’ gene editing tool temporarily rewrites genetics to treat cancer and HIVGeekWire |